Now showing items 1-1 of 1

    • Targeting RIPK1 ubiquitylation to promote anti-tumour immunity 

      Jamal, K (2019-11-30)
      Cancer heterogeneity is a key problem of current therapies leading to resistance. The way cancer cells die can lead to anti-cancer immunity, which is frequently referred to as "immunogenic" cell death. The aim of the project ...